Get started
Nurix Therapeutics, Inc.Nurix Therapeutics, Inc.Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

NRIX chart


Full chart

NRIX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.93 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.91 USD
Net income (FY)
‪−143.95 M‬ USD
Revenue (FY)
‪76.99 M‬ USD
Shares float
‪69.64 M‬
Beta (1Y)
1.75

Employees


Employees (FY)
284
Change (1Y)
−13 −4.38%
Revenue / Employee (1Y)
‪271.08 K‬ USD
Net income / Employee (1Y)
‪−506.86 K‬ USD

About Nurix Therapeutics, Inc.


Sector
Health Technology
CEO
Arthur T. Sands
Headquarters
San Francisco
Website
nurixtx.com
Founded
2009
FIGI
BBG00SDJ8M78
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

NRIX news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of NRIX is 27.32 USD — it has increased by 0.89% in the past 24 hours. Watch Nurix Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Nurix Therapeutics, Inc. stocks are traded under the ticker NRIX.
NRIX stock has risen by 13.41% compared to the previous week, the month change is a 25.53% rise, over the last year Nurix Therapeutics, Inc. has showed a 381.75% increase.
We've gathered analysts' opinions on Nurix Therapeutics, Inc. future price: according to them, NRIX price has a max estimate of 41.00 USD and a min estimate of 16.00 USD. Watch NRIX chart and read a more detailed Nurix Therapeutics, Inc. stock forecast: see what analysts think of Nurix Therapeutics, Inc. and suggest that you do with its stocks.
NRIX reached its all-time high on Dec 14, 2020 with the price of 52.38 USD, and its all-time low was 4.22 USD and was reached on Oct 26, 2023. View more price dynamics on NRIX chart.
See other stocks reaching their highest and lowest prices.
NRIX stock is 3.55% volatile and has beta coefficient of 1.75. Track Nurix Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Nurix Therapeutics, Inc. there?
Today Nurix Therapeutics, Inc. has the market capitalization of ‪1.93 B‬, it has decreased by −4.56% over the last week.
Yes, you can track Nurix Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Nurix Therapeutics, Inc. is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
NRIX earnings for the last quarter are −0.67 USD per share, whereas the estimation was −0.69 USD resulting in a 2.57% surprise. The estimated earnings for the next quarter are −0.67 USD per share. See more details about Nurix Therapeutics, Inc. earnings.
Nurix Therapeutics, Inc. revenue for the last quarter amounts to ‪12.59 M‬ USD, despite the estimated figure of ‪14.97 M‬ USD. In the next quarter, revenue is expected to reach ‪15.37 M‬ USD.
NRIX net income for the last quarter is ‪−48.96 M‬ USD, while the quarter before that showed ‪−44.55 M‬ USD of net income which accounts for −9.90% change. Track more Nurix Therapeutics, Inc. financial stats to get the full picture.
No, NRIX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 284.00 employees. See our rating of the largest employees — is Nurix Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Nurix Therapeutics, Inc. EBITDA is ‪−177.82 M‬ USD, and current EBITDA margin is −183.68%. See more stats in Nurix Therapeutics, Inc. financial statements.
Like other stocks, NRIX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Nurix Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Nurix Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Nurix Therapeutics, Inc. stock shows the buy signal. See more of Nurix Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.